小说的发展 小说的发展
Shohei Tsuchihashi1, Kazuma Nakashima1, Yuta Tarumizu2
1Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto 606-8501, Japan.
Journal of medicinal chemistry
|June 7, 2023
概括
一种新的前列腺特异性膜抗原 (PSMA) 向剂,PSMA-NAT-DA1 (PNT-DA1),显示出增强的亲和力和瘤吸收. 这种PSMA放射性射剂在转移性割抵抗性前列腺癌的临床前模型中表现出优异的抗瘤作用.
科学领域:
- 核医学就是核医学.
- 在瘤学瘤学.
- 放射化学 放射化学是指辐射化学.
背景情况:
- 前列腺特异性膜抗原 (PSMA) 是转移性割抵抗性前列腺癌 (mCRPC) 的关键标.
- 之前针对PSMA的放射性治疗剂,如PSMA-DA1,显示出有希望的结果.
- 增强瘤吸收对于提高放射性疗效至关重要.
研究的目的:
- 设计和评估一种针对PSMA的新型放射性射剂PSMA-NAT-DA1 (PNT-DA1),具有增强瘤积累.
- 在前列腺癌的临床前模型中评估PNT-DA1的诊断和治疗潜力.
主要方法:
- PSMA-NAT-DA1 (PNT-DA1) 通过将脂友性链接剂纳入PSMA-DA1.1中来合成.
- 准备和鉴定了[111In]In-PNT-DA1和 [225Ac]Ac-PNT-DA1的放射性连接体.
- 使用SPECT/CT评估了[111In]In-PNT-DA1的PSMA结合亲和力,瘤吸收和成像性能.
- 在临床前模型中评估了 [225Ac]Ac-PNT-DA1 的抗瘤疗效和毒性.
主要成果:
- 与[111In]In-PSMA-DA1 (Kd = 89.4 nM) 相比,[111In]在PNT-DA1中表现出明显更高的PSMA亲和力 (Kd = 8.20 nM).
- [111In]在PNT-DA1中表现出显著的瘤积累 (48小时内注射剂量/g为131.6%) 和清晰的瘤可视化.
- [225Ac]Ac-PNT-DA1治疗导致瘤显著缩小,毒性最小.
- [225Ac]Ac-PNT-DA1的抗瘤疗效超过了 [225Ac]Ac-PSMA-DA1 和 [225Ac]Ac-PSMA-617 的疗效.
结论:
- PSMA-NAT-DA1 (PNT-DA1) 代表了针对前列腺癌的PSMA向辐射疗法的一个有希望的进步.
- 增强的亲和力和瘤吸收PNT-DA1转化为优越的诊断成像和治疗结果.
- 联合诊断 ([111In]In-PNT-DA1) 和治疗 ([225Ac]Ac-PNT-DA1) 应用为管理mCRPC提供了一个强有力的策略.
相关概念视频
Preclinical Development: Overview
4.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.5K
Genome Size and the Evolution of New Genes
8.0K
While every living organism has a genome of some kind (be it RNA, or DNA), there is considerable variation in the sizes of these blueprints. One major factor that impacts genome size is whether the organism is prokaryotic or eukaryotic. In prokaryotes, the genome contains little to no non-coding sequence, such that genes are tightly clustered in groups or operons sequentially along the chromosome. Conversely, the genes in eukaryotes are punctuated by long stretches of non-coding sequence.
8.0K
Development of Antibiotic Resistance
50
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
50
Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Drug Discovery: Overview
8.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.1K
Development of Immunocompetence
366
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
366


